The pharmaceutical industry in India was valued at US$33 billion in 2017, and generic drugs account for 20 per cent of global exports in terms of volume, making the country the largest provider of generic medicines globally. According to the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, domestic pharmaceutical market turnover reached Rs 129,015 crore (US$18.12 billion) in 2018, growing 9.4 per cent year-on-year and exports revenue was US$17.28 billion in FY18 and US$19.14 billion in FY19. Hyderabad, Mumbai, Pune, Baddi, HimachalPradesh, Chennai, Bangalore, Ahmedabad, Vadodara, Ankleshwar, Vapi, Sikkim and Kolkata are the major pharmaceutical hubs of India.
At Bionics Enviro Tech, we understand the unique challenges and opportunities within India’s dynamic pharmaceutical sector. We are dedicated to providing advanced bioculture solutions that help pharmaceutical companies enhance their operational efficiency, ensure product purity, manage waste responsibly, and meet stringent regulatory standards, contributing to a healthier and more sustainable future.
We provide solutions that directly address key challenges faced by pharmaceutical manufacturers:
Challenge: Maintaining aseptic conditions and preventing microbial contamination are paramount for product safety and efficacy.
Our Solution: Our specialized biocultures help create a balanced microbial environment, outcompeting undesirable microorganisms. This contributes to higher product purity and significantly reduces the risk of costly batch rejections.
Challenge: Maximizing the yield of active pharmaceutical ingredients (APIs) and optimizing fermentation processes are critical for cost-effectiveness and faster production cycles.
Our Solution: Our bioculture formulations enhance metabolic pathways, improve nutrient utilization, and accelerate biochemical reactions. This leads to increased yields and more efficient production of various pharmaceutical compounds.
Challenge: Pharmaceutical manufacturing generates complex, often highly polluted wastewater, requiring advanced treatment to meet increasingly strict environmental regulations.
Our Solution: Our powerful biocultures are engineered to effectively degrade diverse organic pollutants in pharmaceutical effluents. They significantly reduce Chemical Oxygen Demand (COD), Biological Oxygen Demand (BOD), and other critical parameters, ensuring compliance and promoting environmental stewardship.
Challenge: The industry is actively moving towards more sustainable practices, aiming to reduce reliance on harsh chemicals and minimize its environmental footprint.
Our Solution: By offering bio-based alternatives, our bioculture solutions support greener manufacturing processes. They reduce chemical usage, lower energy consumption for effluent treatment, and contribute directly to the industry’s sustainability goals.
Nanozyme Bacterial digestion is the process of bacteria, consuming organic & Inorganic matter. Enzymes act to break the organic & Inorganic matter into water soluble nutrients, which the bacteria digest. Using complex chemical reactions, the organic & Inorganic waste is metabolized down to water and carbon dioxide (the final metabolic waste products), providing the bacteria with energy for growth and reproduction. It may be simply shown by the following equation:
We offer highly specialized bioculture products designed to meet the rigorous demands of the pharmaceutical industry.
Product Description: NANOZYME – BET – ETP – 7003 is a cutting-edge organic semi-solid bioculture specifically engineered for highly efficient Effluent Treatment Plant (ETP) operations in the pharmaceutical sector. It comprises a potent consortium of 60 different, living bacterial cultures, meticulously selected for their robust degradation capabilities.
Our NANOZYME–BET–ETP–7003 delivers exceptional performance in degrading pharmaceutical wastewater contaminants
| Available Form | Organic Semi-Solid Form |
| Number of Bacterial Cultures | 62 Different Bacterial Cultures |
| Stage of Bacterial Cultures | Living Bacteria |
| Number of Bacterial Colonies | 65 x 10-9 CFU/ml |
| Shelf Life | Min One Year |
Preferred Buyer From
| Location | Worldwide |
Impact on Effluent
| Parameters | Percentage of Reduction |
| Sludge Degradation | Zero Sludge |
| Chemical Oxygen Demand (COD) | 95 – 98 % |
| Biological Oxygen Demand (BOD) | 98 – 100 % |
| Colour | 90 – 100 % |
| Odor | 100 % |
| Removal of Suspended & Floatable Organic Debris | 100 % |
| Reduces Total Suspended Solids (TSS) | 92-95% |
| Reduces Total Dissolved Solids (TDS) | Depends on the characteristics of wastewater |
| Increases Dissolved Oxygen (OD) | Min 3 – Max 8 |
CAPACITY : 1MLD
| S.No | PRODUCT DESCRIPTION | UNIT | Quantity | |
|---|---|---|---|---|
| 1 | NANOZYME BET-ETP-7003 PRO | Kgs | 100 | |
| 2 | NANOZYME BET-NUTRI-9003 | Kgs | 50 |
REQUIRED MATERIALS FOR PREPARATION:
NANOZYME INCUBATION METHOD:
| Dosage | Day of Dosage | From 10000 litres of prepared broth Volume of Nanozyme Application to Aeration | ||
|---|---|---|---|---|
| 1st Dosage | 1st to 10 days | 100 Litres / Day | ||
| 2nd Dosage | 11th to 20th Days | 100 Litres / Day | ||
| 3rd Dosage | 21st to 30th Days | 100 Litres / Day |
DOSAGE LOCATION OF NANOZYME CULTURE: AERATION TANK
| S.no | Product Description | Unit | Qty | Unit Price in INR |
|---|---|---|---|---|
| 1 | NANOZYME BET-ANA-9002 | Kgs | 400 | 1200 |
| 2 | NANOZYME BET-NUTRI-9003 | Kgs | 200 | 300 |